[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100100686":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":53,"centralContacts":11,"locations":64,"responsibleParty":86,"collaborators":88,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":98,"sex":104,"minAge":105,"maxAge":11,"enrollmentInfo":106,"targetDuration":11,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":120,"whyStopped":11,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL",null,[13],"Drug: Tenofovir\u002FEmtricitabine (Truvada) and Nevirapine",{"label":15,"type":10,"description":11,"interventionNames":16},"2",[17],"Drug: Tenofovir (Viread) and Lopinavir\u002FRitonavir (Aluvia)",{"label":19,"type":10,"description":11,"interventionNames":20},"3",[21],"Drug: Tenofovir\u002FEmtricitabine (Truvada) and Zidovudine",{"label":23,"type":24,"description":11,"interventionNames":25},"4","ACTIVE_COMPARATOR",[26],"Drug: Tenofovir\u002FEmtricitabine\u002FEfavirenz (Atripla)",[28,35,41,48],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Tenofovir\u002FEmtricitabine (Truvada) and Nevirapine","Tenofovir\u002FEmtricitabine(Truvada) 245\u002F200mg 1cp\u002Fday ; Nevirapine 200mg 2cp\u002Fday after first 14 days",[9],[34],"Truvada",{"type":29,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Tenofovir\u002FEmtricitabine\u002FEfavirenz (Atripla)","Tenofovir\u002FEmtricitabine\u002FEfavirenz (Atripla) 300\u002F200\u002F600mg 1cp\u002Fday",[23],[40],"Atripla",{"type":29,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Tenofovir (Viread) and Lopinavir\u002FRitonavir (Aluvia)","Tenofovir (Viread) 300mg 1cp\u002Fday ; Lopinavir\u002FRitonavir (Aluvia) 400\u002F100mg 4cp\u002Fday",[15],[46,47],"Viread","Aluvia",{"type":29,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"Tenofovir\u002FEmtricitabine (Truvada) and Zidovudine","Tenofovir\u002FEmtricitabine (Truvada) 245\u002F200mg 1cp\u002Fday ; Zidovudine 300mg 2cp\u002Fday",[19],[34],[54,58,61],{"name":55,"affiliation":56,"role":57},"Landman Roland, MD","Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","PRINCIPAL_INVESTIGATOR",{"name":59,"affiliation":60,"role":57},"Sow Papa Salif, MD","Hopital de Fann, Dakar",{"name":62,"affiliation":63,"role":57},"Koulla Shiro Sinata, MD","Hopital Central Yaoundé",[65,76],{"facility":66,"status":11,"city":67,"state":11,"zip":11,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":11},"Hopital Central","Yaoundé","Cameroon","CM",{"type":71,"coordinates":72},"Point",[73,74],11.51667,3.86667,{"lat":74,"lon":73},{"facility":77,"status":11,"city":78,"state":11,"zip":11,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"Hopital de Fann","Dakar","Senegal","SN",{"type":71,"coordinates":82},[83,84],-17.44406,14.6937,{"lat":84,"lon":83},{"type":87,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[89,91,94],{"name":56,"class":90},"OTHER",{"name":92,"class":93},"Gilead Sciences","INDUSTRY",{"name":95,"class":93},"Merck Sharp & Dohme LLC","100100686","phase-3-evaluation-of-4-new-simplified-antiretroviral-treatments-in-naive-hiv-1-infected-patients-in-africa-anrs-12115-dayana-100100686",false,"NCT00573001","Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)","Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde","DAYANA","Inclusion Criteria:\n\n* age over 18 years for Senegal and over 21 years for Cameroon\n* HIV-1 infected patient\n* patient naive from any antiretroviral treatment\n* CD4 cell count over 50 cells per mm3\n* contraceptive method use\n* informed consent signed\n\nExclusion Criteria:\n\n* opportunistic infection ongoing or any other serious pathology\n* ongoing treatment with rifampicine\n* severe renal or hepatic impairment\n* HbSAg positive\n* Hemoglobine under 8g\u002FL\n* Neutrophils under 500 cells per mm3\n* ongoing pregnancy or breastfeeding\n* treatment by contra-indicated drugs (as described in study drugs notices)","ALL","18 Years",{"count":107,"type":108},120,"ACTUAL","INTERVENTIONAL",[111],"PHASE3","The goal of this trial is to demonstrate that new treatments are as effective as a reference triple-agent regimen in driving plasma viral load below the detection limit early during treatment (16 weeks). These simplified treatments involve fewer tablets and intakes, fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor and tenofovir.",[114],"HIV Infections",[116,117,118,119],"naive","HIV-1","simplified treatment","Treatment Experienced","COMPLETED","2012-05-14",{"date":123,"type":124},"2012-05-15","ESTIMATED",{"date":126,"type":11},"2008-07",{"date":128,"type":108},"2011-12",{"name":130,"class":6},"French National Agency for Research on AIDS and Viral Hepatitis",2]